[go: up one dir, main page]

WO2005041920A3 - Pharmazeutische licofelone-formulierung - Google Patents

Pharmazeutische licofelone-formulierung Download PDF

Info

Publication number
WO2005041920A3
WO2005041920A3 PCT/EP2004/012266 EP2004012266W WO2005041920A3 WO 2005041920 A3 WO2005041920 A3 WO 2005041920A3 EP 2004012266 W EP2004012266 W EP 2004012266W WO 2005041920 A3 WO2005041920 A3 WO 2005041920A3
Authority
WO
WIPO (PCT)
Prior art keywords
licofelone
formulation
water soluble
copolymers
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/012266
Other languages
English (en)
French (fr)
Other versions
WO2005041920A2 (de
Inventor
Frank Sievert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merckle GmbH
Original Assignee
Merckle GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle GmbH filed Critical Merckle GmbH
Publication of WO2005041920A2 publication Critical patent/WO2005041920A2/de
Publication of WO2005041920A3 publication Critical patent/WO2005041920A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft eine feste pharmazeutische Formulierung, die Licofelone oder ein physiologisch akzeptables Salz davon und wenigstens ein wasser lösliches Polymer ausgewählt unter Hydroxyalkylcellulosen, Methylcellulose, Polyvinylpyrrolidonen und Copolymeren davon, Polyvinyialkoholen, verseiften oder teilverseiften Copolymeren aus N-Vinylpyrrolidon und Vinylestern, und/oder wenigstens ein wasserlösliches Polyol, das ausgewählt ist unter Polyethylenglykolen mit einem Molekulargewicht im Bereich von 8.000 bis 20.000 und Zuckeralkoholen. Es handelt sich um eine den Wirkstoff rasch freisetzende Formulierung.
PCT/EP2004/012266 2003-10-31 2004-10-29 Pharmazeutische licofelone-formulierung Ceased WO2005041920A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10351035.4 2003-10-31
DE10351035A DE10351035A1 (de) 2003-10-31 2003-10-31 Pharmazeutische Licofelone-Formulierung

Publications (2)

Publication Number Publication Date
WO2005041920A2 WO2005041920A2 (de) 2005-05-12
WO2005041920A3 true WO2005041920A3 (de) 2005-07-14

Family

ID=34485181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/012266 Ceased WO2005041920A2 (de) 2003-10-31 2004-10-29 Pharmazeutische licofelone-formulierung

Country Status (4)

Country Link
AR (1) AR046205A1 (de)
DE (1) DE10351035A1 (de)
TW (1) TW200524592A (de)
WO (1) WO2005041920A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109718220A (zh) * 2017-10-27 2019-05-07 天津药物研究院有限公司 Ml-4000包合物胶囊的制备方法
EP3593792A1 (de) 2018-07-11 2020-01-15 Welding GmbH & Co. KG Pharmazeutische zusammensetzung umfassend 6-(4-chlorphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizin-5-yl-essigsäurecholinsalz
WO2023089636A1 (en) * 2021-11-21 2023-05-25 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of licofelone

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041626A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US20020143033A1 (en) * 1996-02-13 2002-10-03 G.D. Searle & Co. Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
WO2002089791A2 (de) * 2001-04-30 2002-11-14 Zouboulis Christos C Behandlung der akne mit lipoxygenase inhibitoren
WO2003097041A1 (en) * 2002-05-17 2003-11-27 Merckle Gmbh Annelated pyrrole compounds as proton pump inhibitors for treating ulcer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041626A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6136839A (en) * 1995-06-12 2000-10-24 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US20020143033A1 (en) * 1996-02-13 2002-10-03 G.D. Searle & Co. Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
WO2002089791A2 (de) * 2001-04-30 2002-11-14 Zouboulis Christos C Behandlung der akne mit lipoxygenase inhibitoren
WO2003097041A1 (en) * 2002-05-17 2003-11-27 Merckle Gmbh Annelated pyrrole compounds as proton pump inhibitors for treating ulcer

Also Published As

Publication number Publication date
AR046205A1 (es) 2005-11-30
WO2005041920A2 (de) 2005-05-12
DE10351035A1 (de) 2005-05-25
TW200524592A (en) 2005-08-01

Similar Documents

Publication Publication Date Title
WO2002051385A8 (en) Solid dispersions of nitrate active principles
DK1796484T3 (da) Konfektureprodukt
EP1649851A3 (de) Vorgelatinierte Stärke in einer Formulierung mit gesteuerter Freigabe
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
CA2331264A1 (en) Compositions and methods for drug delivery
CA2312710A1 (en) Sustained release formulation containing three different types of polymers and tablet formed therefrom
WO2004010998A8 (en) Sustained-release tablet comprising reboxetine
MA30064B1 (fr) Formulation a liberation prolongee comprenant l'octreotide et deux copolymeres de polylactide-glycolide ou plus
WO2005025499A3 (en) Hydrophobic drug compositions containing reconstitution enhancer
WO2001060335A3 (en) Delivery systems using preformed biodegradable polymer compositions and methods
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO1998009597A3 (en) Cushioning beads and tablet comprising the same capable of forming a suspension
WO2006059029A3 (fr) Solutions viscoelastiques renfermant du hyaluronate de sodium et de l'hydroxypropylmethyl- cellulose, preparation et utilisations
WO2008148742A3 (de) Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
WO2003000777A3 (en) Multi-arm block copolymers as drug delivery vehicles
JP2008539802A5 (de)
WO2001078680A3 (en) Pharmaceutical compositions comprising fluvastatin
CA2341397A1 (en) Immediate release tablet
WO2007068615A3 (en) Hcv prodrug formulation
CA2346868A1 (en) Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
UA94917C2 (ru) Композиции для местного применения
WO2008156217A3 (en) Pharmaceutical solid preparation comprising benzazepines and production method thereof
WO2003059382A3 (en) Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase